The rationale for the potential efficacy of RET inhibitors in colorectal cancer lies in the fact that RET, a receptor tyrosine kinase involved in cell growth and differentiation, can become constitutively active through genetic rearrangements such as fusions in some cancers, including a subset of colorectal cancers. The gene discussed is RET; the disease is colorectal cancer.